Navigation Links
GenVec Reports Fourth Quarter and 2010 Year-End Financial Results
Date:3/10/2011

, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to research and development activities; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of collaborators and third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations.  Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.  These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.

(Tables to follow)GenVec, Inc.Condensed Statements of Operations(in thousands, except per share data)Quarter EndedYear Ended12/31/1012/31/0912/31/1012/31/09(unaudited)Revenues

$5,191$3,355$16,467$13,857Operating expenses:Research and development

4,9205,53020,93624,689General and administrative

1,5262,0708,1527,179Gain on disposal of assets

------(7)Total operating expenses

6,4467,60029,08831,861Operating loss

(1,255)(4,245)(12,621)(18,004)Interest income

11438Interest expense, net

6(66)130(128)Other

244--213(268)Net loss

(1,004)(4,310)$(12,274)$(18,362)Basic and diluted net loss per share

$(0.01)$(0.04)$(0.10)$(0.19)Shares used in computation of basicand diluted net loss per share

129,077106,336126,70997,074GenVec, Inc.Selected Balance Sheet Information(in thousands)As of December 31,20102009Cash, cash equivalents and short-term investments

$35,170$10,961Working capital

31,6897,002Total as
'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. GenVec Forms Collaboration With World-Leading Animal Health Company
2. GenVec Reports Third Quarter 2010 Financial Results
3. GenVec Receives Second-Year Funding From SAIC for HIV and Influenza Vaccine Development
4. GenVec Receives National Cancer Institute Grant to Expand Cancer Program
5. GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting
6. Transgenomic Reports Fourth Quarter Financial Results
7. Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results
8. Six-Month Prospective Multi-Center Study Reports Efficacy Rates for AMS Elevate Anterior and Apical Prolapse Repair System
9. Sinovac Reports Positive Preliminary Phase I Clinical Trial Results for EV71 Vaccine in Adult Group
10. Cardiogenesis Reports Fourth Quarter and Full Year 2010 Results
11. Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 27, 2015  PinnacleHealth CardioVascular Institute enrolled the first patient ... the United States in a trial assessing ... for blockages in the main artery of the leg. The ... potentially less risk for stent fracture or re-narrowing after the ... multicenter clinical trial of the BioMimics 3D Stent System and ...
(Date:8/27/2015)... Aug. 27, 2015  Lightwave Logic, Inc. (OTCQB: ... of Next Generation Photonic Devices and Non-Linear ... high speed fiber-optic data communications and optical computing, ... has been appointed to the Company,s Board of ... field of optoelectronics is widely recognized with wide-ranging ...
(Date:8/27/2015)... , Aug. 27, 2015  CytomX Therapeutics, ... the treatment of cancer, today announced that ... the company,s Board of Directors, has been appointed ... at Eli Lilly and AstraZeneca, and also oversaw ... approved checkpoint inhibitor, at Bristol-Myers Squibb and the ...
Breaking Medicine Technology:First Pennsylvania Patient Treated in Landmark Vascular Study 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 3Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3
... Confirm Robust Efficacy of CIMZIA, BOSTON, Nov. ... new,Phase III data from the RAPID 1 and ... Annual Scientific Meeting (ACR), which show,CIMZIA(R) (certolizumab pegol), ... Factor), given with methotrexate, is significantly,more effective than ...
... Fla., Nov. 7 A new analysis,presented today ... Evaluation Of Rosuvastatin) showed CRESTOR(R) (rosuvastatin calcium) 40,mg ... in four,patient populations at varying levels of risk ... subjects defined by the Framingham risk,assessment tool as ...
Cached Medicine Technology:CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 2CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 3CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 4CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 5CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 6CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 7CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 8New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 2New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 3New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 4New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 5New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 6
(Date:8/27/2015)... (PRWEB) , ... August 28, 2015 , ... This new ... ensure that patients are always scheduled for the next visit, their authorizations are in ... here . , According to Jason Barnes, COO for Genesis Chiropractic Software, growing a ...
(Date:8/27/2015)... Mesa, CA (PRWEB) , ... August 27, 2015 , ... ... to get help, leaving weeks or months later, relapsing and returning again, all at ... under the influence while in sober living homes or soon after leaving facilities who ...
(Date:8/27/2015)... Los Angeles, CA (PRWEB) , ... August 27, 2015 , ... ... Diabetes Association and the American Heart Association have released new guidelines to educate doctors ... that the last update to these particular guidelines came in 2007, so the new ...
(Date:8/27/2015)... ... 27, 2015 , ... In mid-May, Logistics Trust, Inc. (“Logistics ... launch of its Doobster platform, a HIPAA-compliant mobile application that allows medical marijuana ... phones and tablets. Well, Doobster, “The App That Delivers!” is here! ...
(Date:8/27/2015)... ... August 27, 2015 , ... The Naderi Center is proud to announce ... cutting-edge, noninvasive procedure to improve submental fat. The first and only Food and ... surgery. Dr. Kulak is the only Board Certified surgeon in the D.C., Maryland, ...
Breaking Medicine News(10 mins):Health News:A New Webinar Teaches Chiropractors How to Use Compliance Alerts to Manage Patient Relationships 2Health News:National Screenings of Documentary Indicate Burgeoning Questions about the Effectiveness of Addiction Treatment Facilities 2Health News:National Screenings of Documentary Indicate Burgeoning Questions about the Effectiveness of Addiction Treatment Facilities 3Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 2Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 3Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 2Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 3Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 4Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 5Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3
... medical records to be provided at locations throughout ... entered into a clinical collaboration with MinuteClinic, the ... in the United States, at several locations inside ... provide a convenient, seven-day-a-week option for those with ...
... eminent orthopaedic surgeon at the University of Brighton Medical School has ... research on a new orthopaedic prosthesis for shoulder reconstruction. , ... ... Keith Borowsky, an eminent orthopaedic surgeon at the University of Brighton ...
... Court for the Commonwealth of MassachusettsVANCOUVER, Feb. 12 ... ; TSX: QLT) announced that on February 11, ... Massachusetts General Hospital ("MGH"), filed a complaint in ... against QLT Phototherapeutics (Canada), Inc. QLT Phototherapeutics (Canada), ...
... gender also affect chances of having debilitating headaches , , THURSDAY, ... risk of migraine headaches in young and middle-aged adults, suggests ... gender and the way body fat was distributed affected migraine ... were more likely to have migraines than those with smaller ...
... The Bay, a regional resource for hospice and ... care at no charge to all healthcare professionals ... in March. CEUs are available. The ongoing trainings ... in Larkspur. For the schedule of trainings, which ...
... BTEL) announced results for its second quarter ended,December 31, ... diluted share,on revenues of $3,186,000. This compares to net ... of $2,859,000 for the second quarter of last,year. For ... net earnings of,$617,000, or $0.22 per diluted share, on ...
Cached Medicine News:Health News:Cleveland Clinic Enters into Agreement with MinuteClinic 2Health News:Cleveland Clinic Enters into Agreement with MinuteClinic 3Health News:Cleveland Clinic Enters into Agreement with MinuteClinic 4Health News:Force Tester Shoulders The Burden 2Health News:QLT announces that it is named as a defendant in an action 2Health News:QLT announces that it is named as a defendant in an action 3Health News:Belly Fat May Make Migraines More Likely 2Health News:Hospice By The Bay Offers Health Care Professionals Free Training in End-of-Life Care 2Health News:Hospice By The Bay Offers Health Care Professionals Free Training in End-of-Life Care 3Health News:Biotel Announces Profitable Second Quarter Ended December 31, 2008 2
... the first polypropylene mesh specifically designed ... directly addresses the critical issues associated ... delivers maximum visibility, enhanced maneuverability and ... through the trocar.,Visilex mesh is the ...
... technique, recommended for the treatment of ... direct inguinal hernias, provides significant advantages ... less overall dissection and is utilized ... The result is increased patient comfort, ...
... longest available wavelength with a unique flat ... efficacy. The unique flat beam profile consistently ... all targeted structures. The Lyra-I uniquely avoids ... Lyra-I patients are protected by patented continuous ...
... nonabsorbable knitted product for use in ... a highly flexible and compliant material ... surgical adaptability, along with maximal porosity ... Mesh is constructed from polyethylene terephthalate, ...
Medicine Products: